<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01005108</url>
  </required_header>
  <id_info>
    <org_study_id>UPCC 16108</org_study_id>
    <secondary_id>NCI-2009-01315</secondary_id>
    <nct_id>NCT01005108</nct_id>
  </id_info>
  <brief_title>Acupuncture and Gabapentin for Hot Flashes Among Breast Cancer Survivors</brief_title>
  <official_title>Acupuncture and Gabapentin for Hot Flashes Among Breast Cancer Survivors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abramson Cancer Center of the University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abramson Cancer Center of the University of Pennsylvania</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Overall Objectives: The overarching goal is to compare the effectiveness of acupuncture and&#xD;
      gabapentin to their respective placebo controls in the treatment of hot flashes in breast&#xD;
      cancer patients. The investigators primary specific aim will focus on determining the&#xD;
      magnitude of response to placebo acupuncture versus placebo pills on hot flashes (HFs).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 2009</start_date>
  <completion_date type="Actual">January 31, 2014</completion_date>
  <primary_completion_date type="Actual">January 31, 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Daily Hot Flash Diary (DHFD)-Primary Outcome (2 minutes per day)</measure>
    <time_frame>Daily starting from baseline until week 12 and again for one week at week 24.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Demographics -Covariates</measure>
    <time_frame>5 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hot Flash Related Daily Interference Scale (HFRDIS)-Secondary outcome</measure>
    <time_frame>3 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pittsburgh Sleep Quality Index (PSQI) - Secondary outcome</measure>
    <time_frame>6 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Brief Fatigue Inventory (BFI) - Secondary Outcome</measure>
    <time_frame>3 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HADS - Secondary Outcome</measure>
    <time_frame>2 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global Assessment Scale -Secondary Outcome</measure>
    <time_frame>30 seconds</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acupuncture Expectancy Scale (AES) - Secondary Aim</measure>
    <time_frame>1 minute</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Creditability Rating of Acupuncture - Secondary Aim</measure>
    <time_frame>1 minute</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Medication and CAM Usage -Covariates</measure>
    <time_frame>5 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Actigraph Movement Measuring Device</measure>
    <time_frame>24 hrs/day for 3 days</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">120</enrollment>
  <condition>Hot Flashes</condition>
  <arm_group>
    <arm_group_label>placebo pill</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo accupuncture</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>accupuncture</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>gabapentin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gabapentin</intervention_name>
    <description>Use of Gabapentin as a control intervention to evaluate the relative effects and adverse events of acupuncture for hot flashes</description>
    <arm_group_label>accupuncture</arm_group_label>
    <arm_group_label>gabapentin</arm_group_label>
    <arm_group_label>placebo accupuncture</arm_group_label>
    <arm_group_label>placebo pill</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Women 18 years or older with a history of Stage I, II or III breast cancer for at&#xD;
             least 12 months.&#xD;
&#xD;
          2. Have been seen by an oncologist within the previous 6-month period and determined to&#xD;
             be free of disease by clinical examination and history;&#xD;
&#xD;
          3. Experienced at least two hot flashes daily over the seven-day screening period as&#xD;
             based on the Daily Hot Flash Diary.&#xD;
&#xD;
          4. Hot flashes have been present for at least a month before study entry.&#xD;
&#xD;
          5. Willing to use non-hormonal contraceptives during the duration of the study if patient&#xD;
             is premenopausal.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Having metastatic breast cancer ( IV)&#xD;
&#xD;
          2. Currently on chemotherapy or radiation therapy as adjuvant treatment&#xD;
&#xD;
          3. Started hormonal therapies such as tamoxifen or aromatase inhibitors within the last 4&#xD;
             weeks; or plan to change or terminate hormonal therapies in the next 14 weeks.&#xD;
&#xD;
          4. Started or changed with treatments for hot flashes, such as SSRIs or clonidine within&#xD;
             the last 4 weeks; or plan to change or terminate these therapies in the next 14 weeks.&#xD;
&#xD;
          5. Current use of estrogen and/or progestin.&#xD;
&#xD;
          6. Pregnancy&#xD;
&#xD;
          7. Breast feeding&#xD;
&#xD;
          8. Bleeding disorder or current use of warfarin or heparin by patient history because of&#xD;
             the use of needles.&#xD;
&#xD;
          9. Previous use of gabapentin for hot flashes.&#xD;
&#xD;
         10. Current use of any anti-convulsant.&#xD;
&#xD;
         11. Renal dysfunction defined as serum creatinine concentration above 1.25 times the upper&#xD;
             limit of normal&#xD;
&#xD;
         12. Known allergy to gabapentin.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jun J Mao, MD, MSCE</last_name>
    <role>Principal Investigator</role>
    <affiliation>Abramson Cancer Center of the University of Pennsylvania</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Abramson Cancer Center of the Unviersity of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>October 29, 2009</study_first_submitted>
  <study_first_submitted_qc>October 29, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 30, 2009</study_first_posted>
  <disposition_first_submitted>April 13, 2020</disposition_first_submitted>
  <disposition_first_submitted_qc>April 13, 2020</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">April 15, 2020</disposition_first_posted>
  <last_update_submitted>April 13, 2020</last_update_submitted>
  <last_update_submitted_qc>April 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 15, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hot Flashes for Breast Cancer Patients</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hot Flashes</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gabapentin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

